Yes Northwest Bio has stated their intention to file for accelerated approval and should qualify for RMAT designation, so I think it’s highly likely that it has been considered, and may be used eventually. But why haven’t they applied or announced it yet? My point was that the reason may be that they are considering another accelerated approval route first.
DCVax should meet the criteria for an Innovation Passport but it may be too late in development. This is the relevant section of the guidance:
I think regulators understand that there will be a number of innovative treatments that are already in late-stage development when new guidelines were established that may deserve some flexibility on their eligibility. The MHRA, NICE and other stakeholders in the UK are well aware of DCVax, so it certainly would be worthwhile for Northwest Bio to apply.. An acceptance and rapid approval of an innovative treatment for Glioblastoma could be a public and political win for the MHRA and its new pathway as well. And actually the ILAP route would qualify for Project Orbis, which was included in the long list of the benefits of the ILAP that I included at the end of my post.